Endovascular stents for abdominal aortic aneurysms: a systematic review and economic model

D Chambers,1* D Epstein,2 S Walker,2 D Fayter,1 F Paton,1 K Wright,1 J Michaels,3 S Thomas,3 M Sculpher2 and N Woolacott1

1Centre for Reviews and Dissemination, University of York, UK
2Centre for Health Economics, University of York, UK
3Academic Vascular Unit, University of Sheffield, Northern General Hospital, Sheffield, UK

*Corresponding author

Executive summary

Health Technology Assessment 2009; Vol. 13: No. 48
DOI: 10.3310/hta13480
Executive summary

Background

Abdominal aortic aneurysms (AAAs) carry a high risk of rupture, which is associated with a mortality rate of about 80%. AAAs can be treated by surgical repair to prevent rupture. However, open repair involves significant risks and approximately 25% of patients with an AAA requiring surgery are considered unfit for open surgery. Endovascular aneurysm repair (EVAR) is a minimally invasive technique that has been used to treat patients with appropriate aneurysm morphology who are classified as either fit for open repair or unfit. EVAR is used both as an elective procedure and to treat symptomatic and ruptured aneurysms.

Objective

The management options available after diagnosis of AAA can be classified as immediate elective surgery with open repair; immediate elective surgery with EVAR; surveillance with an option to defer surgery; or a decision to rule out surgery entirely. The objective of this assessment is to determine the clinical effectiveness and cost-effectiveness of EVAR for repair of infrarenal AAAs in patients at varying levels of risk, including those who are appropriate for open repair and those who are not.

Methods

A systematic review of the clinical effectiveness of EVAR was performed. Recent systematic reviews were used to identify randomised controlled trials (RCTs) and other clinical studies. Additional searches (2005–February 2008) were conducted to search for recent RCTs, publications relating to named registries [Registry of Endovascular Treatment of Abdominal Aortic Aneurysms (RETA) and the European Collaborators on Stent–Graft Techniques for Abdominal Aortic Aneurysm Repair (EUROSTAR) for EVAR, and the National Vascular Database (NVD) for open surgery] and studies on the relationship between patients’ baseline risks and outcomes. The following bibliographic databases were searched: BIOSIS Previews,® Cumulative Index to Nursing and Allied Health Literature (CINAHL), Cochrane Central Register of Controlled Trials, EMBASE, ISI Proceedings, MEDLINE,® MEDLINE® In-Process & Other Non-Indexed Citations, Science Citation Index and Zetoc Conferences. Searches were not restricted by language or study design and studies written in any language were eligible for inclusion in the review. Studies of EVAR in patients with asymptomatic or symptomatic and ruptured or unruptured infrarenal AAAs were included. Conventional open repair, non-surgical treatment for AAA (sometimes referred to as ‘best medical treatment’) or surveillance (sometimes referred to as ‘watchful waiting’) were the appropriate comparators. Only studies reporting at least one of the following outcomes were included: 30-day mortality rate; aneurysm-related mortality; all-cause mortality; health-related quality of life (HRQoL); adverse effects and complications; and reintervention rates including conversion from EVAR to open procedure and secondary intervention. When appropriate, meta-analysis was employed to estimate a summary measure of treatment effect on relevant outcomes based on intention to treat analyses.

A second systematic review was undertaken to identify and compare existing cost-effectiveness analyses of EVAR compared with open surgery and non-surgical interventions. This review included submissions of economic analyses made by EVAR device manufacturers.

Two new decision models were also developed to inform the review. The first compared the cost-effectiveness of EVAR versus open repair in patients with a large aneurysm (≥ 5.5 cm) for whom the decision to operate has been taken. The second decision model, complementary to the first, compared options of early surgery (with EVAR or open repair), watchful waiting and no surgical intervention. Both models investigated the cost-effectiveness of the strategies in patients of varying age, aneurysm size and level of operative fitness. Four fitness levels were defined in the analysis, given a patient’s age and aneurysm size: good, moderate, poor and very poor.
Results

Clinical effectiveness

Six RCTs were included in the review. Four compared EVAR and open surgery in patients with unruptured AAAs who were fit for open repair. One RCT compared EVAR with non-surgical management of patients deemed unfit for open repair. A small RCT compared EVAR and open repair in patients with ruptured AAAs. There are five ongoing trials from which results are currently unavailable. The limited data reported by the NVD and RETA registries, and the ‘older’ devices used and non-current data reported by RETA, highlight the importance of the EUROSTAR data and findings. Thirty-four studies evaluated the role of patients’ baseline characteristics in predicting the risks of particular outcomes after EVAR. Three studies evaluated existing scoring systems and one study evaluated the development of a model for assessing risks. However, the majority of the risk modelling studies investigated specific risk factors using multiple regression analysis. The majority of these studies were based on data from the EUROSTAR registry with likely overlap of patients.

Compared with open repair, EVAR reduces operative mortality (odds ratio 0.35, 95% CI 0.19 to 0.63) and aneurysm-related mortality over the medium term (hazard ratio 0.49, 95% CI 0.29 to 0.83) but offers no significant difference in all-cause mortality at mid-term follow-up. EVAR was associated with increased rates of complications and reinterventions and these are not offset by any increase in HRQoL.

There is limited RCT evidence comparing EVAR with non-surgical management in patients unfit for open repair. EVAR trial 2 found no differences in mortality outcomes between groups but this finding cannot be taken as definitive because substantial numbers of patients randomised to non-surgical management crossed over to receive surgical repair of their aneurysm. This may indicate that the benefits of EVAR over no intervention may require more than 4 years of follow-up to become apparent.

The results from these trials are complemented by data from registries, in particular the EUROSTAR registry data relating to devices in current use.

Cost-effectiveness

The systematic review of the economic evidence identified six published decision models. Of the five models comparing EVAR and open repair, two were constructed after the operative mortality results of the good-quality RCTs were published and are considered to be relevant for the decision in the UK. Both concluded that EVAR was not cost-effective on average at a threshold of £20,000 per quality-adjusted life-year (QALY). One model compared EVAR with no surgical intervention. This model was constructed before the results of the EVAR trial 2 were published. The model concluded that EVAR would be on average more cost-effective than no surgical intervention in unfit patients at a threshold of £20,000 per QALY. One model was submitted by a manufacturer (Medtronic). This model concluded that EVAR was more cost-effective than open repair for fit patients at a threshold of £20,000 per QALY.

The main findings of the York economic evaluations (base-case models at a threshold of £20,000 per QALY) are:

- EVAR is not cost-effective compared with open repair on average given base-case assumptions at a threshold of £30,000 per QALY.
- Results are very sensitive to model assumptions. EVAR may be more cost-effective than open repair if the relative costs of the procedure have fallen, reinterventions are relatively less frequent and follow-up surveillance is currently less intensive compared with the base-case assumptions.
- Results are sensitive to the baseline risk of operative mortality. A subgroup analysis found that EVAR was likely to be cost-effective compared with open repair in patients with poor operative risk and unlikely to be cost-effective in patients with good operative risk. A validated and accepted fitness score is needed to distinguish individual patients by operative risk.
- An exploratory analysis was undertaken to evaluate management options in patients who would not be considered suitable for open surgery, that is, in patients of very poor fitness. This model was based on uncertain data about the natural history of untreated aneurysm. This suggested that the cost-effectiveness of EVAR may be sensitive to aneurysm size and patient’s age at operation. Further research in these areas would be important to inform future modelling work.
- Indicative modelling results suggest that EVAR may be cost-effective for small aneurysms (< 5.5 cm) in some patient groups. Ongoing RCTs will provide further evidence relating to these patients. A review of the current
Executive summary: Endovascular stents for abdominal aortic aneurysms

Guideline that aneurysms should not be operated on if less than 5.5 cm should then be considered.

Conclusions

Implications for service provision

Based on the results of this assessment of clinical and cost-effectiveness, and using a set of base-case assumptions, open repair is likely to be considered cost-effective compared with EVAR on average in patients considered fit for open surgery. Cost-effectiveness may vary with fitness. EVAR is likely to be more cost-effective than open repair for patients at higher risk of operative mortality. There is considerable uncertainty in this analysis, in particular concerning the relative cost of procedures and rate of reinterventions. An exploratory study suggested that EVAR may be more cost-effective than medical treatment or watchful waiting for some groups of patients unfit for open repair, depending on age and aneurysm size. Evidence does not currently support EVAR for the treatment of ruptured aneurysms.

Suggested research priorities

- Further follow-up of the existing UK trials (EVAR trial 1, EVAR trial 2) should be undertaken.
- The relative procedure costs and device costs should be investigated further.
- Opportunities for individual patient meta-analysis of all RCTs relating to EVAR should be sought.
- Further research is needed on the rates of late complications, reinterventions and aneurysm-related mortality after EVAR, in particular those associated with the most recent generation of devices.
- The optimal surveillance policy following EVAR should be investigated.
- The extent to which the relative treatment effect of EVAR on operative mortality can be assumed constant across subgroups of patients should be further investigated.
- Research is required into how to implement the best available risk scoring systems for the management of AAA into decision-making in routine clinical practice.
- Research is required into the natural history of untreated AAA to determine more reliably when surgical intervention is optimal. The analysis should investigate the impact of different levels and determinants of patient fitness as well as aneurysm size and anatomy.
- A well-defined and well-conducted RCT of EVAR versus watchful waiting, reflecting current clinical practice, is warranted. However, given the difficulties of conducting RCTs in the management of AAA it is probably advisable that the collection of data through the existing, established registries in the UK, particularly RETA (for EVAR) and NVD (for open repair), should be continued.

Publication

How to obtain copies of this and other HTA programme reports

An electronic version of this publication, in Adobe Acrobat format, is available for downloading free of charge for personal use from the HTA website (www.hta.ac.uk). A fully searchable CD-ROM is also available (see below).

Printed copies of HTA monographs cost £20 each (post and packing free in the UK) to both public and private sector purchasers from our Despatch Agents.

Non-UK purchasers will have to pay a small fee for post and packing. For European countries the cost is £2 per monograph and for the rest of the world £3 per monograph.

You can order HTA monographs from our Despatch Agents:

– fax (with credit card or official purchase order)
– post (with credit card or official purchase order or cheque)
– phone during office hours (credit card only).

Additionally the HTA website allows you either to pay securely by credit card or to print out your order and then post or fax it.

Contact details are as follows:

HTA Despatch           Email: orders@hta.ac.uk
c/o Direct Mail Works Ltd          Tel: 02392 492 000
4 Oakwood Business Centre       Fax: 02392 478 555
Downley, HAVANT PO9 2NP, UK          Fax from outside the UK: +44 2392 478 555

NHS libraries can subscribe free of charge. Public libraries can subscribe at a very reduced cost of £100 for each volume (normally comprising 30–40 titles). The commercial subscription rate is £300 per volume. Please see our website for details. Subscriptions can be purchased only for the current or forthcoming volume.

Payment methods

Paying by cheque
If you pay by cheque, the cheque must be in pounds sterling, made payable to Direct Mail Works Ltd and drawn on a bank with a UK address.

Paying by credit card
The following cards are accepted by phone, fax, post or via the website ordering pages: Delta, Eurocard, Mastercard, Solo, Switch and Visa. We advise against sending credit card details in a plain email.

Paying by official purchase order
You can post or fax these, but they must be from public bodies (i.e. NHS or universities) within the UK.
We cannot at present accept purchase orders from commercial companies or from outside the UK.

How do I get a copy of HTA on CD?

Please use the form on the HTA website (www.hta.ac.uk/htacd.htm). Or contact Direct Mail Works (see contact details above) by email, post, fax or phone. HTA on CD is currently free of charge worldwide.

The website also provides information about the HTA programme and lists the membership of the various committees.
The Health Technology Assessment (HTA) programme, part of the National Institute for Health Research (NIHR), was set up in 1993. It produces high-quality research information on the effectiveness, costs and broader impact of health technologies for those who use, manage and provide care in the NHS. ‘Health technologies’ are broadly defined as all interventions used to promote health, prevent and treat disease, and improve rehabilitation and long-term care.

The research findings from the HTA programme directly influence decision-making bodies such as the National Institute for Health and Clinical Excellence (NICE) and the National Screening Committee (NSC). HTA findings also help to improve the quality of clinical practice in the NHS indirectly in that they form a key component of the ‘National Knowledge Service’.

The HTA programme is needs led in that it fills gaps in the evidence needed by the NHS. There are three routes to the start of projects.

First is the commissioned route. Suggestions for research are actively sought from people working in the NHS, from the public and consumer groups and from professional bodies such as royal colleges and NHS trusts. These suggestions are carefully prioritised by panels of independent experts (including NHS service users). The HTA programme then commissions the research by competitive tender.

Second, the HTA programme provides grants for clinical trials for researchers who identify research questions. These are assessed for importance to patients and the NHS, and scientific rigour.

Third, through its Technology Assessment Report (TAR) call-off contract, the HTA programme commissions bespoke reports, principally for NICE, but also for other policy-makers. TARs bring together evidence on the value of specific technologies.

Some HTA research projects, including TARs, may take only months, others need several years. They can cost from as little as £40,000 to over £1 million, and may involve synthesising existing evidence, undertaking a trial, or other research collecting new data to answer a research problem.

The final reports from HTA projects are peer reviewed by a number of independent expert referees before publication in the widely read journal series Health Technology Assessment.

---

Criteria for inclusion in the HTA journal series

Reports are published in the HTA journal series if (1) they have resulted from work for the HTA programme, and (2) they are of a sufficiently high scientific quality as assessed by the referees and editors.

Reviews in Health Technology Assessment are termed ‘systematic’ when the account of the search, appraisal and synthesis methods (to minimise biases and random errors) would, in theory, permit the replication of the review by others.

The research reported in this issue of the journal was commissioned and funded by the HTA programme on behalf of NICE as project number 07/09/01. The protocol was agreed in August 2007. The assessment report began editorial review in April 2008 and was accepted for publication in February 2009. The authors have been wholly responsible for all data collection, analysis and interpretation, and for writing up their work. The HTA editors and publisher have tried to ensure the accuracy of the authors’ report and would like to thank the referees for their constructive comments on the draft document. However, they do not accept liability for damages or losses arising from material published in this report.

The views expressed in this publication are those of the authors and not necessarily those of the HTA programme or the Department of Health.

Editor-in-Chief: Professor Tom Walley CBE
Series Editors: Dr Aileen Clarke, Professor Chris Hyde, Dr John Powell, Dr Rob Riemsma and Professor Ken Stein